Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Anti-apoptotic BCL2 family proteins are key regulators of cancer cell survival.
• MCL1 is highly expressed in castration-resistant prostate cancer (PCa), correlating with poor prognosis.
• Targeting MCL1 is a promising strategy for inducing cancer cell death.

Purpose of the Study:

• To investigate the therapeutic potential of targeting MCL1 and BCLXL in prostate cancer.
• To evaluate the role of UCHL3 in regulating MCL1 expression.
• To assess the efficacy of co-targeting MCL1 and BCLXL in preclinical PCa models.

Main Methods:

• Utilized BH3 mimetics to target MCL1.
• Employed siRNA to downregulate UCHL3.
• Tested co-targeting strategies in patient-derived and mouse PCa models.
• Assessed apoptotic cell death as a primary endpoint.

Main Results:

• Targeting MCL1 with BH3 mimetics induced apoptosis in a subset of PCa cell lines.
• siRNA targeting of UCHL3 showed an off-target effect on MCL1 regulation.
• Co-targeting MCL1 and BCLXL effectively triggered apoptotic cell death in preclinical PCa models.
• MCL1 and BCLXL blockade synergized to promote cancer cell death.

Conclusions:

• Targeting the intrinsic apoptosis pathway, specifically MCL1 and BCLXL, is a viable therapeutic strategy for lethal prostate cancer.
• Further research is needed to develop cancer-specific killing strategies for improved patient outcomes.
• Understanding off-target effects is crucial for studying MCL1 biology and developing targeted therapies.